Here are the DEF 14A proxy statements from Regional Health PRP PFD A (RHEPA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RHEPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RHEPA filings page.
Regional Health Properties, Inc. (RHEP) is soliciting shareholder votes at its November 10, 2026 annual meeting to elect six directors and ratify Cherry Bekaert, LLP as independent registered public accounting firm for the year ending December 31, 2026. Three director seats are voted on by common shareholders, one by Series B preferred holders and two by Series D preferred holders. The Board recommends voting “FOR” both proposals. Shareholders of record in those classes as of September 21, 2026 are eligible to vote.
The company’s 2025 pay-versus-performance figures list net income of $3.37 million, following net losses of $3.218 million in 2024 and $3.888 million in 2023. Marlie Davis, who became chief financial officer in May 2026, has an initial annual base salary of $265,000, a target bonus opportunity of $100,000, 35,000 restricted stock units and an option to purchase 35,000 common shares.
Regional Health Properties, Inc. is asking shareholders to vote at its 2025 Annual Meeting on board elections, pay matters and an updated equity plan. Seven directors will be elected, with different voting groups for common stock, 12.5% Series B preferred and Series D preferred holders. Common shareholders are also asked to approve an Amended and Restated 2023 Omnibus Incentive Compensation Plan, which would increase the common shares authorized for awards by 550,000, raising the total plan pool from 225,000 to 775,000 shares, including up to 775,000 incentive stock options. The proxy explains that 149,000 shares have already been issued under the 2023 plan, 117,998 shares are subject to outstanding awards and 76,000 shares remain available. Shareholders will also cast advisory votes on executive compensation, how often to hold Say‑on‑Pay, and on ratifying Cherry Bekaert as independent auditor for 2025.